NCT01539590View on ClinicalTrials.gov

Study to Evaluate the Safety and Activity of BB3 to Treat Heart Attack

PHASE2TerminatedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

July 31, 2013

Study Completion Date

November 30, 2013

Conditions
Myocardial Infarction
Interventions
DRUG

BB3

Daily intravenous administration of 2 mg/kg BB3 for four (4) days

DRUG

Normal saline

Daily intravenous administration for four (4) days. The volume of normal saline will vary by estimated weight.

Trial Locations (2)

55417-1139

Minneapolis Heart Institute Foundation, Minneapolis

06520

Yale University Medical Center, New Haven

Sponsors
All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Angion Biomedica Corp

INDUSTRY

NCT01539590 - Study to Evaluate the Safety and Activity of BB3 to Treat Heart Attack | Biotech Hunter | Biotech Hunter